Quantification of SARS-CoV-2 spike protein expression from mRNA vaccines using isotope dilution mass spectrometry

Sutton, William J.H.; Branham, Paul J.; Williamson, Yulanda M.; Cooper, Hans C.; Najjar, Fabio N.; Pierce-Ruiz, Carrie L.; Barr, John R.; Williams, Tracie L.

doi:10.1016/j.vaccine.2023.04.044

Cited by 4 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Delivery of the antigenic protein and its analogue in mRNA form initially yields different pharmacokinetics. According to one of the studies, based on the results of an in vitro experiment, 1 pmol of the spike protein was obtained using 6 pmol of mRNA vaccine for 24 hours during transfection of BHK cell culture ( 42 ). According to our earlier experiments, when we delivered 10 μg of mRNA (approximately 20 pmol) encoding the B11 antibody against botulinum toxin we achieved a maximum antibody concentration in mouse serum of 99 ng/mL, which translates to about 2.35 pmol of antibody per average serum volume of an 18-g mouse ( 21 ).…”

Section: Discussionmentioning

confidence: 99%

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

Mazunina,

Gushchin,

Kleymenov

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Seasonal influenza remains a serious global health problem, leading to high mortality rates among the elderly and individuals with comorbidities. Vaccination is generally accepted as the most effective strategy for influenza prevention. While current influenza vaccines are effective, they still have limitations, including narrow specificity for certain serological variants, which may result in a mismatch between vaccine antigens and circulating strains. Additionally, the rapid variability of the virus poses challenges in providing extended protection beyond a single season. Therefore, mRNA technology is particularly promising for influenza prevention, as it enables the rapid development of multivalent vaccines and allows for quick updates of their antigenic composition. mRNA vaccines have already proven successful in preventing COVID-19 by eliciting rapid cellular and humoral immune responses. In this study, we present the development of a trivalent mRNA vaccine candidate, evaluate its immunogenicity using the hemagglutination inhibition assay, ELISA, and assess its efficacy in animals. We demonstrate the higher immunogenicity of the mRNA vaccine candidate compared to the inactivated split influenza vaccine and its enhanced ability to generate a cross-specific humoral immune response. These findings highlight the potential mRNA technology in overcoming current limitations of influenza vaccines and hold promise for ensuring greater efficacy in preventing seasonal influenza outbreaks.

show abstract

Section: Discussionmentioning

confidence: 99%

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

Mazunina,

Gushchin,

Kleymenov

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Delivery of the antigenic protein and its analogue in mRNA form initially yields different pharmacokinetics. According to one of the studies, based on the results of an in vitro experiment, 1 pmol of the spike protein was obtained using 6 pmol of mRNA vaccine for 24 hours during transfection of BHK cell culture [36]. According to our earlier experiments, when we delivered 10 μg of mRNA (approximately 20 pmol) encoding the B11 antibody against botulinum toxin we achieved a maximum antibody concentration in mouse serum of 99 ng/mL, which translates to about 2.35 pmol of antibody per average serum volume of an 18-g mouse [22].…”

Section: Discussionmentioning

confidence: 99%

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

Mazunina,

Gushchin,

Kleymenov

et al. 2023

Preprint

View full text Add to dashboard Cite

Seasonal influenza remains a serious global health problem, leading to high mortality rates among the elderly and individuals with comorbidities. It also imposes a substantial economic burden through increased absenteeism during periods of active pathogen circulation. Vaccination is generally accepted as the most effective strategy for influenza prevention. As both influenza A and B viruses circulate and cause seasonal epidemics, vaccines need to include multiple antigens derived from different viral subtypes. While current influenza vaccines are effective, they still have limitations, including narrow specificity for certain serological variants, which may result in a mismatch between vaccine antigens and circulating strains. Additionally, the rapid variability of the virus poses challenges in providing extended protection beyond a single season. Therefore, mRNA technology is particularly promising for influenza prevention, as it enables the rapid development of multivalent vaccines and allows for quick updates of their antigenic composition. mRNA vaccines have already proven successful in preventing COVID-19 by eliciting rapid cellular and humoral immune responses. In this study, we present the development of a trivalent mRNA vaccine candidates, evaluate its immunogenicity using the hemagglutination inhibition assay, and assess its efficacy in animals. We demonstrate the higher immunogenicity of the mRNA vaccine candidates compared to the inactivated split influenza vaccine and its enhanced ability to generate a cross-specific humoral immune response. These findings highlight the potential mRNA technology in overcoming current limitations of influenza vaccines and hold promise for ensuring greater efficacy in preventing seasonal influenza outbreaks.

show abstract

An antibody-free evaluation of an mRNA COVID-19 vaccine

Branham,

Cooper,

Williamson

et al. 2024

Biologicals

View full text Add to dashboard Cite

Quantification of SARS-CoV-2 spike protein expression from mRNA vaccines using isotope dilution mass spectrometry

Cited by 4 publications

References 45 publications

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

An antibody-free evaluation of an mRNA COVID-19 vaccine

Contact Info

Product

Resources

About